Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 12, 2008, Pages 4320-4325

  Yu, Dong ^a   Putta, Mallikarjuna R ^a   Bhagat, Lakshmi ^a   Dai, Meiru ^a   Wang, Daqing ^a   Trombino, Anthony F ^a   Sullivan, Tim ^a   Kandimalla, Ekambar R ^a   Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIINFECTIVE AGENT; CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MEMBRANE RECEPTOR; OLIGONUCLEOTIDE; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; UNCLASSIFIED DRUG;

AGONIST; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; COOLING; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; EMBRYO; FEMALE; HEATING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; MELTING POINT; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE TRANSITION; PRIMATE; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; STRUCTURE ANALYSIS; TH1 CELL; THERMAL ANALYSIS;

ANIMALS; CELL LINE; CELLS, CULTURED; CPG ISLANDS; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON-ALPHA; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; TH1 CELLS; TOLL-LIKE RECEPTOR 9; TRANSITION TEMPERATURE;

EID: 57049134825     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00701-08     Document Type: Article

References (28)

1. Agrawal, S., and E. R. Kandimalla. 2007. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem. Soc. Trans. 35:1461-1467.
2. Cong, Y. P., S. S. Song, L. Bhagat, R. K. Pandey, D. Yu, E. R. Kandimalla, and S. Agrawal. 2003. Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells. Biochem. Biophys. Res. Commun. 310:1133-1139.
3. Hartmann, G., J. Battiany, H. Poeck, M. Wagner, M. Kerkmann, N. Lubenow, S. Rothenfusser, and S. Endres. 2003. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur. J. Immunol. 33:1633-1641.
4. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745.
5. Kandimalla, E. R., L. Bhagat, Y. P. Cong, R. K. Pandey, D. Yu, Q. Zhao, and S. Agrawal. 2003. Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Biochem. Biophys. Res. Commun. 306:948-953.
6. Kandimalla, E. R., L. Bhagat, Y.-P. Cong, D. Yu, F.-G. Zhu, D. Wang, J. X. Tang, J.-Y. Tang, C. F. Knetter, E. Lien, and S. Agrawal. 2003. A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc. Natl. Acad. Sci. USA 100:14303-14308.
7. Kandimalla, E. R., L. Bhagat, Y. Li, D. Yu, D. Wang, Y. P. Cong, S. S. Song, J. X. Tang, T. Sullivan, and S. Agrawal. 2005. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2′-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists. Proc. Natl. Acad. Sci. USA 102:6925-6930.
8. Kandimalla, E. R., L. Bhagat, D. Yu, Y. Cong, J. Tang, and S. Agrawal. 2002. Conjugation of ligands at the 5′-end of CpG DNA affects immunostimulatory activity. Bioconjug. Chem. 13:966-974.
9. Kandimalla, E. R., L. Bhagat, D. Wang, D. Yu, J. Tang, H. Wang, P. Huang, R. Zhang, and S. Agrawal. 2003. Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res. 31:2393-2400.
10. Klinman, D. M. 2004. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4:249-258.
11. Klinman, D. M., A. K. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg. 1996. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 93:2879-2883.
12. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20:709-760.
13. Krieg, A. M., A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
14. Krug, A., S. Rothenfusser, V. Hornung, B. Jahrsdorfer, S. Blackwell, Z. K. Ballas, S. Endres, A. M. Krieg, and G. Harmann. 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur. J. Immunol. 31:2154-2163.
15. Marshall, J. D., K. Fearon, C. Abbate, S. Subramanian, P. Yee, J. Gregorio, R. L. Coffman, and G. vanNest. 2003. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J. Leukoc. Biol. 73:781-792.
16. McHutchison, J. G., B. R. Bacon, S. C. Gordon, E. Lawitz, M. Schiffman, N. H. Afdhal, I. M. Jacobson, A. Muir, M. Al-Adhami, M. L. Morris, J. A. Lekstrom-Himes, S. M. Efler, and H. L. Davis. 2007. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with hepatitis C virus. Hepatology 46:1341-1349.
17. Messina, J. P., G. S. Gilkeson, and D. S. Pisetsky. 1991. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J. Immunol. 147:1759-1764.
18. Stacey, K. J., M. J. Sweet, and D. A. Hume. 1996. Macrophages ingest and are activated by bacterial DNA. J. Immunol. 157:2116-2122.
19. Tokunaga, T., H. Yamamoto, S. Shimada, H. Abe, T. Fukuda, Y. Fujisawa, Y. Furutani, O. Yano, T. Kataoka, T. Sudo, N. Makiguchi, and T. Suganuma. 1984. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 72:955-962.
20. Verthelyi, D., K. J. Ishii, M. Gursel, F. Takeshita, and D. M. Klinman. 2001. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J. Immunol. 166:2372-2377.
21. Vicari, A. P., T. Schmalbach, J. Lekstrom-Himes, M. L. Morris, M. J. Al-Adhami, C. Laframboise, P. Leese, A. M. Krieg, S. M. Efler, and H. L. Davis. 2007. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic Toll-like receptor 9 agonist. Antivir. Ther. 12:741-751.
22. Vollmer, J., R. Weeratna, P. Payette, M. Jurk, C. Schetter, M. Laucht, T. Wader, S. Tluk, M. Liu, H. L. Davis, and A. M. Krieg. 2004. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34:251-262.
23. Yamamoto, S., E. Kuramoto, S. Shimada, and T. Tokunaga. 1988. In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn. J. Cancer Res. 79:866-873.
24. Yi, A.-K., and A. M. Krieg. 1998. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J. Immunol. 161:4493-4497.
25. Yu, D., E. R. Kandimalla, L. Bhagat, J. Y. Tang, Y. Cong, J. Tang, and S. Agrawal. 2002. 'Immunomers' - novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res. 30: 4460-4469.
26. Yu, D., Q. Zhao, E. R. Kandimalla, and S. Agrawal. 2000. Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg. Med. Chem. Lett. 10:2585-2588.
27. Yu, D., F. G. Zhu, L. Bhagat, H. Wang, E. R. Kandimalla, R. Zhang, and S. Agrawal. 2002. Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem. Biophys. Res. Commun. 297:83-90.
28. Zhao, Q., J. Temsamani, R. Z. Zhou, and S. Agrawal. 1997. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 7:495-502.